Cargando…
A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin
INTRODUCTION: Tumourigenesis attributed to residual undifferentiated cells in a graft is considered to be a significant issue in cell therapy using human pluripotent stem cells. To ensure the safety of regenerative medicine derived from pluripotent stem cells, residual undifferentiated cells must be...
Autores principales: | Haramoto, Yoshikazu, Onuma, Yasuko, Mawaribuchi, Shuuji, Nakajima, Yoshiro, Aiki, Yasuhiko, Higuchi, Kumiko, Shimizu, Madoka, Tateno, Hiroaki, Hirabayashi, Jun, Ito, Yuzuru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Regenerative Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240284/ https://www.ncbi.nlm.nih.gov/pubmed/32462059 http://dx.doi.org/10.1016/j.reth.2020.03.017 |
Ejemplares similares
-
rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma
por: Mawaribuchi, Shuuji, et al.
Publicado: (2020) -
Elimination of Tumorigenic Human Pluripotent Stem Cells by a Recombinant Lectin-Toxin Fusion Protein
por: Tateno, Hiroaki, et al.
Publicado: (2015) -
Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells
por: Furuta, Tomoaki, et al.
Publicado: (2021) -
mRNA and miRNA expression profiles in an ectoderm-biased substate of human pluripotent stem cells
por: Mawaribuchi, Shuuji, et al.
Publicado: (2019) -
Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer:
(18)F‐labeled rBC2LCN lectin
por: Kuroda, Yukihito, et al.
Publicado: (2023)